학술논문
Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study.
Document Type
Academic Journal
Author
Saito T; Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan. takuro1119@hotmail.com.; Kurokawa Y; Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan.; Fujitani K; Department of Gastroenterological Surgery, Osaka General Medical Center, Osaka, Japan.; Kawabata R; Department of Surgery, Osaka Rosai Hospital, Sakai, Japan.; Takeno A; Department of Surgery, Kansai Rosai Hospital, Amagasaki, Japan.; Mikami J; Department of Surgery, Sakai City Medical Center, Sakai, Japan.; Endo S; Department of Surgery, Higashi-Osaka Medical Center, Higashi-Osaka, Japan.; Matsuyama J; Department of Surgery, Yao Municipal Hospital, Yao, Japan.; Akamaru Y; Department of Surgery, Ikeda City Hospital, Osaka, Japan.; Hirota M; Department of Surgery, Toyonaka Municipal Hospital, Toyonaka, Japan.; Kishi K; Department of Surgery, Osaka Police Hospital, Osaka, Japan.; Urakawa S; Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan.; Yamamoto K; Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan.; Tanaka K; Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan.; Takahashi T; Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan.; Oka M; Department of Immuno-Oncology, Kawasaki Medical School, Okayama, Japan.; Wada H; Department of Clinical Research in Tumor Immunology, Osaka University Graduate School of Medicine, Osaka, Japan.; Eguchi H; Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan.; Doki Y; Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan.
Source
Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
Subject
Language
English
Abstract
Background: No reliable marker has been identified to predict postoperative recurrence of gastric cancer. We designed a clinical trial to investigate the utility of serum NY-ESO-1 antibody responses as a predictive marker for postoperative recurrence in gastric cancer.
Methods: A multicenter prospective study was conducted between 2012 and 2021. Patients with resectable cT3-4 gastric cancer were included. Postoperative NY-ESO-1 and p53 antibody responses were serially evaluated every 3 months for 1 year in patients with positive preoperative antibody responses. The recurrence rate was assessed by the positivity of antibody responses at 3 and 12 months postoperatively.
Results: Among 1001 patients, preoperative NY-ESO-1 and p53 antibody responses were positive in 12.6% and 18.1% of patients, respectively. NY-ESO-1 antibody responses became negative postoperatively in non-recurrent patients (negativity rates; 45% and 78% at 3 and 12 months, respectively), but remained positive in recurrent patients (negativity rates; 9% and 8%, respectively). p53 antibody responses remained positive in non-recurrent patients. In multivariate analysis, NY-ESO-1 antibody positivity at 3 months (P < 0.03) and 12 months (P < 0.001) were independent prognostic factors for a shorter recurrence-free interval.
Conclusions: Serum NY-ESO-1 antibodies may be a useful predictive marker for postoperative recurrence in gastric cancer.
Clinical Trial Registration: UMIN000007925.
(© 2024. The Author(s).)
Methods: A multicenter prospective study was conducted between 2012 and 2021. Patients with resectable cT3-4 gastric cancer were included. Postoperative NY-ESO-1 and p53 antibody responses were serially evaluated every 3 months for 1 year in patients with positive preoperative antibody responses. The recurrence rate was assessed by the positivity of antibody responses at 3 and 12 months postoperatively.
Results: Among 1001 patients, preoperative NY-ESO-1 and p53 antibody responses were positive in 12.6% and 18.1% of patients, respectively. NY-ESO-1 antibody responses became negative postoperatively in non-recurrent patients (negativity rates; 45% and 78% at 3 and 12 months, respectively), but remained positive in recurrent patients (negativity rates; 9% and 8%, respectively). p53 antibody responses remained positive in non-recurrent patients. In multivariate analysis, NY-ESO-1 antibody positivity at 3 months (P < 0.03) and 12 months (P < 0.001) were independent prognostic factors for a shorter recurrence-free interval.
Conclusions: Serum NY-ESO-1 antibodies may be a useful predictive marker for postoperative recurrence in gastric cancer.
Clinical Trial Registration: UMIN000007925.
(© 2024. The Author(s).)